By George Glover
Organon shares were surging on Monday after Indian drugmaker Sun Pharmaceutical Industries said it had agreed to buy the women's health company.
Organon stock jumped 17% to $13.14 ahead of the opening bell, having surged 31% on Friday after a report said Sun would raise its offer.
Sun's Mumbai-listed shares added 7%. Futures tracking the S&P 500 were flat, with investors reluctant to make any major moves ahead of a flurry of Big Tech earnings.
Sun agreed to buy Organon, which develops therapies for reproductive health, contraception, and fertility, for $14 a share in an all-cash deal with an enterprise value of $11.75 billion, the two companies said in a press release on Sunday.
Big pharma mergers and acquisition volumes are expected to surge this year as companies seek to replenish pipelines. Biogen, Eli Lilly, and Merck were among the drugmakers to land notable deals last month.
Write to George Glover at george.glover@dowjones.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 27, 2026 08:18 ET (12:18 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.